Doxycycline Hyclate Ph.Eur ( DrugBank: Doxycycline )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 167 | Marfan syndrome | 1 |
167. Marfan syndrome
Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-023612-14-GB (EUCTR) | 08/03/2013 | 20/12/2012 | The Oxford Marfan Trial | A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 | Marfan syndrome. MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Aprovel Product Name: Aprovel INN or Proposed INN: Irbesartan Trade Name: Vibrox 100mg Capsules Product Name: Vibrox INN or Proposed INN: Doxycycline Hyclate Ph.Eur | Clinical Trials and Research Governance | NULL | Not Recruiting | Female: yes Male: yes | 56 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |